查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587475

美國臨床試驗市場規模、佔有率、趨勢分析報告：按階段、按適應症、按研究設計、按申辦者、按服務、細分市場預測，2025-2030 年

U.S. Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication, By Study Design, By Indication by Study Design, By Sponsor, By Service, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國臨床試驗市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年美國臨床試驗市場規模將達到577.9億美元，2025年至2030年複合年成長率為6.30%。

美國慢性病盛行率的上升和對臨床試驗的需求不斷成長正在推動市場成長。

預計未來八年被診斷出罹患癌症的人數將增加數倍。儘管腫瘤學領域的研究顯著增加了倖存者的數量，但預計全球癌症患者的數量將會增加。胰臟癌預後較差，存活期僅1～3年。每天約有 13 人被診斷出患有胃腸道基質腫瘤。美國每年診斷出超過 60,000 例腎細胞癌新病例，這表明癌症盛行率不斷增加，並且需要針對多種癌症進行有效治療方法。由於美國疫情爆發，研發投資預計將增加，推動產業成長。

COVID-19 大流行已停止了新的研究計劃，並將資源重新分配給其他疾病。由於邊境關閉，臨床試驗樣本的供應鏈也受到干擾。因此，這個市場一片混亂。然而，COVID-19 因應措施開拓了新市場，徹底改變了臨床試驗的進行方式。分散/虛擬臨床試驗就是這樣的方法之一。虛擬臨床試驗在目前的 COVID-19 情況下發揮著非常重要的作用。虛擬就診和遠端患者監護為參與者提供了選擇和安心，以最大限度地降低風險。監控小工具、軟體工具和行動電話讓參與者家用中完成實驗。

美國臨床試驗市場報告亮點

  • 2024年，三期試驗佔據了最高的銷售佔有率。這些臨床試驗更為重要，因為它們涉及 300 至 3000 名參與者，而且持續時間較長。因此，這是最昂貴的階段。
  • 從試驗設計來看，干預設計細分市場在美國市場佔據主導地位，在 2024 年佔據最大的銷售佔有率。
  • 有跡象表明，腫瘤學領域在 2024 年佔據了最大的收益佔有率。這種成長是由於癌症患者數量的增加。因此，大量資金花在腫瘤學臨床試驗。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章美國臨床試驗市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 配套市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 監管狀況
  • 技術景觀
  • 定價模式分析
  • 臨床試驗定量分析，2024
  • 美國臨床試驗市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析
  • 產品平臺分階段分析
    • 正在開發的治療方法
    • 正在開發的疫苗

第4章美國臨床試驗市場：階段估計與趨勢分析

  • 細分儀表板
  • 臨床試驗市場：2024 年和 2030 年階段變異分析和市場佔有率
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章美國臨床試驗市場：試驗設計估算與趨勢分析

  • 細分儀表板
  • 臨床試驗市場：研究設計變異分析和市場佔有率，2024 年和 2030 年
  • 侵擾性的
  • 觀察性的
  • 擴展訪問

第6章美國臨床試驗市場：適應症估計與趨勢分析

  • 細分儀表板
  • 臨床試驗市場：適應症變異分析和市場佔有率，2024 年和 2030 年
  • 自體免疫/發炎
    • 類風濕性關節炎
    • 多發性硬化症
    • 骨關節炎
    • 大腸激躁症（IBS）
    • 其他
  • 疼痛管理
    • 慢性疼痛
    • 急性疼痛
  • 腫瘤學
    • 血癌
    • 固態腫瘤
    • 其他
  • 中樞神經系統症狀
    • 癲癇
    • 帕金森氏症 (PD)
    • 亨丁頓舞蹈症
    • 中風
    • 創傷性腦損傷 (TBI)
    • 肌萎縮側索硬化症（ALS）
    • 肌肉再生
    • 其他
  • 糖尿病
  • 肥胖
  • 心血管
  • 其他

第7章美國臨床試驗市場：依試驗設計與適應症進行估算與趨勢分析

  • 細分儀表板
  • 臨床試驗市場：適應症變異分析和市場佔有率，2024 年和 2030 年
  • 自體免疫/發炎
    • 侵擾性的
    • 觀察性的
    • 擴展訪問
  • 疼痛管理
    • 侵擾性的
    • 觀察性的
    • 擴展訪問
  • 腫瘤學
    • 侵擾性的
    • 觀察性的
    • 擴展訪問
  • 中樞神經系統症狀
    • 侵擾性的
    • 觀察性的
    • 擴展訪問
  • 糖尿病
    • 侵擾性的
    • 觀察性的
    • 擴展訪問
  • 肥胖
    • 侵擾性的
    • 觀察性的
    • 擴展訪問
  • 心血管
    • 侵擾性的
    • 觀察性的
    • 擴展訪問
  • 其他
    • 侵擾性的
    • 觀察性的
    • 擴展訪問

第8章美國臨床試驗市場：服務評估與趨勢分析

  • 細分儀表板
  • 臨床試驗市場：申辦者變化分析和市場佔有率，2024 年和 2030 年
  • 通訊協定設計
  • 場地標識
  • 病患招募
  • 化驗服務
  • 生物分析測試服務
  • 臨床試驗資料管理服務
  • 其他

第9章美國臨床試驗市場：申辦者預估及趨勢分析

  • 細分儀表板
  • 臨床試驗市場：申辦者變化分析和市場佔有率，2024 年和 2030 年
  • 製藥和生物製藥公司
  • 醫療設備公司

第10章競爭格局

  • 市場參與企業分類
    • 市場領導者
    • 新興玩家
  • 2024 年市場分析
  • 主要企業簡介
    • IQVIA
    • Fortrea Inc.
    • PAREXEL International Corporation
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories
    • ICON Plc
    • Wuxi AppTec Inc.
    • Medpace
    • Syneos Health
    • AstraZeneca
    • Merck &Co.
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Pfizer
    • Caidya
Product Code: GVR-4-68039-580-4

U.S. Clinical Trials Market Growth & Trends:

The U.S. clinical trials market size is estimated to reach USD 57.79 billion by 2030, registering a CAGR of 6.30% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.

The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry's growth.

The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has also been interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind to minimize risks. Monitoring gadgets, software tools, and mobile phones enable participants to complete the experiment from their homes.

U.S. Clinical Trials Market Report Highlights:

  • In 2024, the phase III dominated the market with highest revenue share. These trials are more crucial as they involve 300 to 3000 participants and have a longer period of time. Thus, it is the most expensive phase
  • By study design, the interventional design segment dominated the U.S. market and accounted for the largest revenue share in 2024.
  • Based on indication, the oncology segment held the largest revenue share in 2024. This growth is due to the growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Regulatory Landscape
  • 3.4. Technological Landscape
  • 3.5. Pricing Model Analysis
  • 3.6. Clinical Trial Volume Analysis, 2024
  • 3.7. U.S. Clinical Trials Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL Analysis
    • 3.7.3. COVID-19 Impact Analysis
  • 3.8. Product Pipeline Analysis by Stage
    • 3.8.1. Therapeutics in Development
    • 3.8.2. Vaccines in Development

Chapter 4. U.S. Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Clinical Trials Market: Phase Movement Analysis & Market Share, 2024 & 2030
  • 4.3. Phase I
    • 4.3.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Phase II
    • 4.4.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Phase III
    • 4.5.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Phase IV
    • 4.6.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Clinical Trials Market: Study Design Movement Analysis & Market Share, 2024 & 2030
  • 5.3. Interventional
    • 5.3.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Observational
    • 5.4.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Expanded Access
    • 5.5.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
  • 6.3. Autoimmune/Inflammation
    • 6.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Rheumatoid Arthritis
      • 6.3.2.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Multiple Sclerosis
      • 6.3.3.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. Osteoarthritis
      • 6.3.4.1. Osteoarthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Irritable Bowel Syndrome (IBS)
      • 6.3.5.1. Irritable Bowel Syndrome (IBS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Others
      • 6.3.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Pain Management
    • 6.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Chronic Pain
      • 6.4.2.1. Chronic Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Acute Pain
      • 6.4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Oncology
    • 6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Blood Cancer
      • 6.5.2.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Solid Tumors
      • 6.5.3.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Others
      • 6.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. CNS Conditions
    • 6.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Epilepsy
      • 6.6.2.1. Epilepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Parkinson's Disease (PD)
      • 6.6.3.1. Parkinson's Disease (PD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Huntington's Disease
      • 6.6.4.1. Huntington's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Stroke
      • 6.6.5.1. Stroke Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Traumatic Brain Injury (TBI)
      • 6.6.6.1. Traumatic Brain Injury (TBI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Amyotrophic Lateral Sclerosis (ALS)
      • 6.6.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.8. Muscle Regeneration
      • 6.6.8.1. Muscle Regeneration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.9. Others
      • 6.6.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Diabetes
    • 6.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Obesity
    • 6.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Cardiovascular
    • 6.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
  • 7.3. Autoimmune/Inflammation
    • 7.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Interventional
      • 7.3.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Observational
      • 7.3.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Expanded Access
      • 7.3.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Pain Management
    • 7.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Interventional
      • 7.4.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Observational
      • 7.4.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Expanded Access
      • 7.4.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Interventional
      • 7.5.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Observational
      • 7.5.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. Expanded Access
      • 7.5.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. CNS Conditions
    • 7.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Interventional
      • 7.6.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Observational
      • 7.6.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Expanded Access
      • 7.6.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Diabetes
    • 7.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Interventional
      • 7.7.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Observational
      • 7.7.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.4. Expanded Access
      • 7.7.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Obesity
    • 7.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. Interventional
      • 7.8.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Observational
      • 7.8.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. Expanded Access
      • 7.8.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9. Cardiovascular
    • 7.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.9.2. Interventional
      • 7.9.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.9.3. Observational
      • 7.9.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.9.4. Expanded Access
      • 7.9.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10. Others
    • 7.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.10.2. Interventional
      • 7.10.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.10.3. Observational
      • 7.10.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.10.4. Expanded Access
      • 7.10.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Clinical Trials Market: Service Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
  • 8.3. Protocol Designing
    • 8.3.1. Protocol Designing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Site Identification
    • 8.4.1. Site Identification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Patient Recruitment
    • 8.5.1. Patient Recruitment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Laboratory Services
    • 8.6.1. Laboratory Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Bioanalytical Testing Services
    • 8.7.1. Bioanalytical Testing Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Clinical Trial Data Management Services
    • 8.8.1. Clinical Trial Data Management Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9. Others
    • 8.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. U.S. Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
  • 9.3. Pharmaceutical & Biopharmaceutical Companies
    • 9.3.1. Pharmaceutical & Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Medical Device Companies
    • 9.4.1. Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Market Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Position Analysis, 2024
  • 10.3. Key Company Profiles
    • 10.3.1. IQVIA
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Fortrea Inc.
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. PAREXEL International Corporation
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Thermo Fisher Scientific Inc.
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Charles River Laboratories
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. ICON Plc
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Wuxi AppTec Inc.
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Medpace
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Syneos Health
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. AstraZeneca
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Merck & Co.
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Eli Lilly and Company
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Novo Nordisk A/S
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Pfizer
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives
    • 10.3.15. Caidya
      • 10.3.15.1. Company Overview
      • 10.3.15.2. Financial Performance
      • 10.3.15.3. Service Benchmarking
      • 10.3.15.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. U.S. Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 4. U.S. Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 5. U.S. Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 6. U.S. Clinical Trials Market, Indication by Study Design, 2018 - 2030 (USD Million)
  • Table 7. U.S. Clinical Trials Market, by Service, 2018 - 2030 (USD Million)
  • Table 8. U.S. Clinical Trials Market, by Sponsor, 2018 - 2030 (USD Million)
  • Table 9. Participant's Overview
  • Table 10. Financial Performance
  • Table 11. Service Benchmarking
  • Table 12. Strategic Initiatives

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Clinical Trials Market, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 10 PESTEL by SWOT Analysis
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 U.S. Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13 U.S. Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Clinical Trials Market, for Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Clinical Trials Market, for Interventional, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Clinical Trials Market, for Observational, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Clinical Trials Market, for Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Clinical Trials Market, for Autoimmune/Inflammation, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Clinical Trials Market, for Rheumatoid Arthritis, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Clinical Trials Market, for Multiple Sclerosis, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Clinical Trials Market, for Osteoarthritis, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Clinical Trials Market, for Irritable Bowel Syndrome (IBS), 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Clinical Trials Market, for Pain Management, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. Clinical Trials Market, for Chronic Pain, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Clinical Trials Market, for Acute Pain, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Clinical Trials Market, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Clinical Trials Market, for Blood Cancer, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Clinical Trials Market, for Solid Tumors, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Clinical Trials Market, for CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Clinical Trials Market, for Epilepsy, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Clinical Trials Market, for Parkinson's Disease (PD), 2018 - 2030 (USD Million)
  • Fig. 35 U.S. Clinical Trials Market, for Huntington's Disease, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Clinical Trials Market, for Stroke, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. Clinical Trials Market, for Traumatic Brain Injury (TBI), 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Clinical Trials Market, for Amyotrophic Lateral Sclerosis (ALS), 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Clinical Trials Market, for Muscle Regeneration, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. Clinical Trials Market, for Diabetes, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Clinical Trials Market, for Obesity, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Clinical Trials Market, for Cardiovascular, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Clinical Trials Market, for Autoimmune/Inflammation Interventional, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. Clinical Trials Market, for Autoimmune/Inflammation Observational, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. Clinical Trials Market, for Autoimmune/Inflammation Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. Clinical Trials Market, for Pain Management Interventional, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. Clinical Trials Market, for Pain Management Observational, 2018 - 2030 (USD Million)
  • Fig. 50 U.S. Clinical Trials Market, for Pain Management Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. Clinical Trials Market, for Oncology Interventional, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. Clinical Trials Market, for Oncology Observational, 2018 - 2030 (USD Million)
  • Fig. 53 U.S. Clinical Trials Market, for Oncology Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 54 U.S. Clinical Trials Market, for CNS Conditions Interventional, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. Clinical Trials Market, for CNS Conditions Observational, 2018 - 2030 (USD Million)
  • Fig. 56 U.S. Clinical Trials Market, for CNS Conditions Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 57 U.S. Clinical Trials Market, for Diabetes Interventional, 2018 - 2030 (USD Million)
  • Fig. 58 U.S. Clinical Trials Market, for Diabetes Observational, 2018 - 2030 (USD Million)
  • Fig. 59 U.S. Clinical Trials Market, for Diabetes Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 60 U.S. Clinical Trials Market, for Obesity Interventional, 2018 - 2030 (USD Million)
  • Fig. 61 U.S. Clinical Trials Market, for Obesity Observational, 2018 - 2030 (USD Million)
  • Fig. 62 U.S. Clinical Trials Market, for Obesity Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 63 U.S. Clinical Trials Market, for Cardiovascular Interventional, 2018 - 2030 (USD Million)
  • Fig. 64 U.S. Clinical Trials Market, for Cardiovascular Observational, 2018 - 2030 (USD Million)
  • Fig. 65 U.S. Clinical Trials Market, for Cardiovascular Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 66 U.S. Clinical Trials Market, for Other Indications Interventional, 2018 - 2030 (USD Million)
  • Fig. 67 U.S. Clinical Trials Market, for Other Indications Observational, 2018 - 2030 (USD Million)
  • Fig. 68 U.S. Clinical Trials Market, for Other Indications Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 69 U.S. Clinical Trials Market, for Protocol Designing, 2018 - 2030 (USD Million)
  • Fig. 70 U.S. Clinical Trials Market, for Site Identification, 2018 - 2030 (USD Million)
  • Fig. 71 U.S. Clinical Trials Market, for Patient Recruitment, 2018 - 2030 (USD Million)
  • Fig. 72 U.S. Clinical Trials Market, for Laboratory Services, 2018 - 2030 (USD Million)
  • Fig. 73 U.S. Clinical Trials Market, for Bioanalytical Testing Services, 2018 - 2030 (USD Million)
  • Fig. 74 U.S. Clinical Trials Market, for Clinical Trial Data Management Services, 2018 - 2030 (USD Million)
  • Fig. 75 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 76 U.S. Clinical Trials Market, for Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 77 U.S. Clinical Trials Market, for Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 78 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)